猴痘的临床表现与诊疗随访

doi:10.35541/cjd.20220688

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (1): 76-81.doi: 10.35541/cjd.20220688

• 猴痘病毒感染专栏综述 • 上一篇下一篇

猴痘的临床表现与诊疗随访

杜方智,张栩,王千秋

中国医学科学院、北京协和医学院皮肤病研究所中国疾病预防控制中心性病控制中心临床防治室，南京 210042

收稿日期:2022-09-29 修回日期:2022-10-24 发布日期:2023-01-03
通讯作者: 王千秋 E-mail:wangqq@ncstdlc.org

Monkeypox: clinical manifestations, diagnosis, treatment and follow-up

Du Fangzhi, Zhang Xu, Wang Qianqiu

Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Clinical Prevention and Control of STD, National Center for STD Control, Chinese Center for Disease Control and Prevention, Nanjing 210042, China

Received:2022-09-29 Revised:2022-10-24 Published:2023-01-03
Contact: Wang Qianqiu E-mail:wangqq@ncstdlc.org

摘要/Abstract

摘要： 【摘要】目的猴痘疫情目前正在全球蔓延，我国面临较大的输入风险。熟悉和掌握猴痘的临床表现和诊疗方法是应对未来风险的重要举措之一。本文总结猴痘的主要临床表现，综述现有的诊疗指南和相关研究，包括诊断、治疗、随访和特殊人群的处理，供临床医生和防治人员参考和借鉴。

关键词: 猴痘, 诊断, 治疗

Abstract: 【Abstract】 The world is suffering from the monkeypox epidemic, and China is facing a great risk of monkeypox importation. Understanding and mastering clinical manifestations, diagnosis and treatment of monkeypox is one of the important measures to respond to future crises. This review summarizes updated guidelines and relevant studies, and covers main clinical manifestations, diagnosis, treatment and follow-up of monkeypox patients, as well as management of special populations, aiming to provide references for clinicians and prevention workers.

Key words: Monkeypox, Diagnosis, Treatment

杜方智张栩王千秋. 猴痘的临床表现与诊疗随访[J]. 中华皮肤科杂志, 2023,56(1):76-81. doi:10.35541/cjd.20220688

Du Fangzhi, Zhang Xu, Wang Qianqiu. Monkeypox: clinical manifestations, diagnosis, treatment and follow-up[J]. Chinese Journal of Dermatology, 2023, 56(1): 76-81.doi:10.35541/cjd.20220688

参考文献 43

［1］	Shchelkunov SN, Totmenin AV, Babkin IV, et al. Human monkeypox and smallpox viruses: genomic comparison［J］. FEBS Lett, 2001,509（1）:66⁃70. doi: 10.1016/s0014⁃5793（01）03144⁃1.
［2］	McCollum AM, Damon IK. Human monkeypox［J］. Clin Infect Dis, 2014,58（2）:260⁃267. doi: 10.1093/cid/cit703.
［3］	American College of Emergency Physicians. ACEP monkeypox field guide［EB/OL］. （2022⁃07⁃08）［2022⁃11⁃02］. https://www.acep.org/monkeypox⁃field⁃guide/cover⁃page/.
［4］	Centers for Disease Control and Prevention. About Monkeypox［EB/OL］. （Updated 2022⁃07⁃22）［2022⁃11⁃02］. https://www.cdc.gov/poxvirus/monkeypox/about.html.
［5］	Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox⁃a potential threat? A systematic review［J/OL］. PLoS Negl Trop Dis, 2022,16（2）:e0010141. doi: 10.1371/journal.pntd.0010141.
［6］	Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis［J］. Lancet Infect Dis, 2004,4（1）:15⁃25. doi: 10.1016/s1473⁃3099（03）00856⁃9.
［7］	Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries ⁃ April⁃June 2022［J］. N Engl J Med, 2022,387（8）:679⁃691. doi: 10.1056/NEJMoa22 07323.
［8］	Orviz E, Negredo A, Ayerdi O, et al. Monkeypox outbreak in Madrid （Spain）: clinical and virological aspects［J］. J Infect, 2022,85（4）:412⁃417. doi: 10.1016/j.jinf.2022.07.005.
［9］	Jezek Z, Szczeniowski M, Paluku KM, et al. Human monkeypox: clinical features of 282 patients［J］. J Infect Dis, 1987,156（2）:293⁃298. doi: 10.1093/infdis/156.2.293.
［10］	Yinka⁃Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 2017⁃18: a clinical and epidemiological report［J］. Lancet Infect Dis, 2019,19（8）:872⁃879. doi: 10.1016/S1473⁃3099（19）30294⁃4.
［11］	Centers for Disease Control and Prevention. Case definitions for use in the 2022 monkeypox response［EB/OL］. （Updated 2022⁃07⁃22）［2022⁃11⁃02］. https://www.cdc.gov/poxvirus/monkeypox/clinicians/case⁃definition.html.
［12］	Peterson E, Kantele A, Koopmans M, et al. Human monkeypox: epidemiological and clinical characteristics, diagnosis, and prevention［J］. Infect Dis Clin North Am, 2019,33（4）:1027⁃1043. doi: 10.1016/j.idc.2019.03.001.
［13］	Osadebe L, Hughes CM, Shongo Lushima R, et al. Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo［J］. PLoS Negl Trop Dis, 2017,11（9）:e0005857. doi: 10.1371/journal.pntd.0005857.
［14］	Singhal T, Kabra SK, Lodha R. Monkeypox: a review［J］. Indian J Pediatr, 2022,89（10）:955⁃960. doi: 10.1007/s12098⁃022⁃04348⁃0.
［15］	Patel A, Bilinska J, Tam J, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series［J］. BMJ, 2022,378:e072410. doi: 10.1136/bmj⁃2022⁃072410.
［16］	Tarín⁃Vicente EJ, Alemany A, Agud⁃Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study［J］. Lancet, 2022,400（10353）:661⁃669. doi: 10. 1016/S0140⁃6736（22）01436⁃2.
［17］	Australian Government Department of Heath and Aged Care. Australian national notifiable diseases case definition［EB/OL］. （2022⁃08⁃01）［2022⁃11⁃02］. https://www.health.gov.au/resources/publications/monkeypox⁃virus⁃infection⁃surveillance⁃case⁃definition.
［18］	European Centre for Disease Prevention and Control, World Health Organization European Region. Joint ECDC⁃WHO regional office for Europe monkeypox surveillance bulletin［EB/OL］. （2022⁃09⁃21）［2022⁃11⁃02］. https://www.who.int/europe/publications/m/item/joint⁃ecdc⁃who⁃regional⁃office⁃for⁃europe⁃monkeypox⁃surveillance⁃bulletin⁃⁃21⁃september⁃2022.
［19］	World Heath Organization. Clinical management and infection prevention and control for monkeypox: interim rapid response guidance［EB/OL］. （2022⁃06⁃10）［2022⁃11⁃02］. https://www.who.int/publications/i/item/WHO⁃MPX⁃Clinical⁃and⁃IPC⁃2022.1.
［20］	中华人民共和国国家卫生健康委员会. 猴痘诊疗指南（2022年版）［EB/OL］. （2022⁃06⁃14）［2022⁃11⁃02］. http://www.nhc.gov.cn/yzygj/s7653p/202206/d687b12fe8b84bbfaede2c7a5ca596ec.
	shtml.
［21］	Vaughan AM, Cenciarelli O, Colombe S, et al. A large multi⁃country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022［J］. Euro Surveill, 2022,27（36）. doi: 10.2807/1560⁃7917.ES.2022.27.36.2200620.
［22］	Kannan S, Shaik Syed Ali P, Sheeza A. Monkeypox: epidemiology, mode of transmission, clinical features, genetic clades and molecular properties［J］. Eur Rev Med Pharmacol Sci, 2022,26（16）:5983⁃5990. doi: 10.26355/eurrev_202208_29540.
［23］	Harris E. What to know about monkeypox［J］. JAMA, 2022,327（23）:2278⁃2279. doi: 10.1001/jama.2022.9499.
［24］	Tutu van Furth AM, van der Kuip M, van Els AL, et al. Paediatric monkeypox patient with unknown source of infection, the Netherlands, June 2022［J］. Euro Surveill, 2022,27（29）. doi: 10.2807/1560⁃7917.ES.2022.27.29.2200552.
［25］	Damon IK. Status of human monkeypox: clinical disease, epidemiology and research［J］. Vaccine, 2011,29 Suppl 4:D54⁃59. doi: 10.1016/j.vaccine.2011.04.014.
［26］	Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK［J］. Lancet Infect Dis, 2022,22（8）:1153⁃1162. doi: 10.1016/S1473⁃3099（22）00228⁃6.
［27］	Stern D, Olson VA, Smith SK, et al. Rapid and sensitive point⁃of⁃care detection of Orthopoxviruses by ABICAP immunofiltration［J］. Virol J, 2016,13（1）:207. doi: 10.1186/s12985⁃016⁃0665⁃5.
［28］	Diaz JH. The disease ecology, epidemiology, clinical manifestations, management, prevention, and control of increasing human infections with animal ortho poxviruses［J］. Wilderness Environ Med, 2021,32（4）:528⁃536. doi: 10.1016/j.wem.2021.08.003.
［29］	Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management［J］. Viruses, 2022,14（2）. doi: 10.3390/v14020192.
［30］	Hoff NA, Morier DS, Kisalu NK, et al. Varicella coinfection in patients with active monkeypox in the Democratic Republic of the Congo［J］. Ecohealth, 2017,14（3）:564⁃574. doi: 10.1007/s10393⁃017⁃1266⁃5.
［31］	Ramoni S, Maronese CA, Morini N, et al. Syphilis and monkeypox co⁃infection: coincidence, synergy or asymptomatic carriage?［J］. Travel Med Infect Dis, 2022,50:102447. doi: 10.1016/j.tmaid.2022.102447.
［32］	Sherwat A, Brooks JT, Birnkrant D, et al. Tecovirimat and the treatment of monkeypox ⁃ past, present, and future considerations［J］. N Engl J Med, 2022,387（7）:579⁃581. doi: 10.1056/NEJMp2210125.
［33］	Desai AN, Thompson GR 3rd, Neumeister SM, et al. Compassionate use of tecovirimat for the treatment of monkeypox infection［J］. JAMA, 2022,328（13）:1348⁃1350. doi: 10.1001/jama.2022.15336.
［34］	De Clercq E. Cidofovir in the therapy and short⁃term prophylaxis of poxvirus infections［J］. Trends Pharmacol Sci, 2002,23（10）:456⁃458. doi: 10.1016/s0165⁃6147（02）02091⁃6.
［35］	Khawaja F, Batista MV, El Haddad L, et al. Resistant or refractory cytomegalovirus infections after hematopoietic cell trans⁃plantation: diagnosis and management［J］. Curr Opin Infect Dis, 2019,32（6）:565⁃574. doi: 10.1097/QCO.0000000000000607.
［36］	Berhanu A, King DS, Mosier S, et al. Impact of ST⁃246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice［J］. Vaccine, 2010,29（2）:289⁃303. doi: 10.1016/j.vaccine.2010.10.039.
［37］	Russo AT, Berhanu A, Bigger CB, et al. Co⁃administration of tecovirimat and ACAM2000™ in non⁃human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge［J］. Vaccine, 2020,38（3）:644⁃654. doi: 10.1016/j.vaccine.2019.10.049.
［38］	Perez Duque M, Ribeiro S, Martins JV, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022［J］. Euro Surveill, 2022,27（22）. doi: 10.2807/1560⁃7917.ES.2022.27.22.2200424.
［39］	Iñigo Martínez J, Gil Montalbán E, Jiménez Bueno S, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022［J］. Euro Surveill, 2022,27（27）. doi: 10.2807/1560⁃7917.ES.2022.27.27. 2200471.
［40］	UK Health Security Agency. Investigation into monkeypox outbreak in England: technical briefing 3［EB/OL］. （Updated 2022⁃09⁃23）［2022⁃11⁃02］. https://www.gov.uk/government/publications/monkeypox⁃outbreak⁃technical⁃briefings/investigation⁃into⁃monkeypox⁃outbreak⁃in⁃england⁃technical⁃briefing⁃3.
［41］	Hoffmann C, Jessen H, Wyen C, et al. Clinical characteristics of monkeypox virus infections among men with and without HIV: a large outbreak cohort in Germany［J］. HIV Med, 2022. doi: 10.1111/hiv.13378.
［42］	Mbala PK, Huggins JW, Riu⁃Rovira T, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo［J］. J Infect Dis, 2017,216（7）:824⁃828. doi: 10.1093/infdis/jix260.
［43］	Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events［J］. Paediatr Drugs, 2009,11（5）:309⁃321. doi: 10.2165/11316080⁃000000000⁃00000.

[1]	洪芷榆谢红付李吉黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 0(3): 20220128-e20220128.
[2]	任芬芬王鹏张景展康晓静. 基于网络药理学预测中药在抗卡波西肉瘤血管生成治疗中的潜在有效成分及分子作用机制[J]. 中华皮肤科杂志, 2023, 0(3): 20220140-e20220140.
[3]	陈启韬李煜乾邵光辉朱晶朱麒麟李中明杜旭峰范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210803-e20210803.
[4]	中华医学会皮肤性病学分会玫瑰痤疮研究中心中国医师协会皮肤科医师分会玫瑰痤疮专业组. A型肉毒毒素皮内注射治疗玫瑰痤疮持久性红斑及潮红专家共识[J]. 中华皮肤科杂志, 2023, 56(1): 16-21.
[5]	李巍李政. 【开放获取】典型与非典型表现的特应性皮炎[J]. 中华皮肤科杂志, 2023, 56(1): 1-4.
[6]	雷杰豪洪为松林福全胡文婷许爱娥. 体外培养节段型白癜风样无色素痣皮损黑素细胞及其临床意义[J]. 中华皮肤科杂志, 2022, 55(9): 798-802.
[7]	樊碧娆陈喜雪王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681.
[8]	曹淼崇杉胡新媛朱学骏王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675.
[9]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[10]	徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652.
[11]	王媛李志量李锁荆可孙超梁桂熔张寒梅冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561.
[12]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[13]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[14]	吕莎王爽武寒飞张明瑞胡馨李福秋. 孢子丝菌病研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 629-632.
[15]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.

猴痘的临床表现与诊疗随访

Monkeypox: clinical manifestations, diagnosis, treatment and follow-up

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

Metrics

本文评价

推荐阅读 10